FID-007 in Treating Participants With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of PEOX-based polymer encapsulated
paclitaxel FID-007 (FID-007) in treating participants with malignant neoplasms that have
spread to other places in the body and do not respond to treatment. FID-007 is a packaged
form of the chemotherapy drug paclitaxel, and uses a polyethylozaxoline (PEOX) polymer which
may allow the drug to reach deeper into tumors and less into normal cells by being smaller.